Guidelines for the use of radiopharmaceuticals targeting prostate-specific membrane antigen

Title: Guidelines for the use of radiopharmaceuticals targeting prostate-specific membrane antigen
Edition: Original
Classification: Standard guideline
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users:
Evidence classification method: This consensus mainly includes two types of evidence: First, high-level evidence-based medical evidence (Category 1), which is unanimously agreed by the expert group and strongly recommended (A); Second, the level of evidence is slightly lower (Category 2), but the expert group basically agrees, and it is moderately recommended (B). Other levels of evidence will not be currently included.
Development unit: Chinese Society of Nuclear Medicine
Registration time: 2023-05-23
Registration number: PREPARE-2023CN353
Purpose of the guideline: